Discovery and clinical introduction of first-in-class imipridone ONC201. - Wikidata - wikimedia - TriplyDB

Discovery and clinical introduction of first-in-class imipridone ONC201.

Discovery and clinical introduction of first-in-class imipridone ONC201.

http://www.wikidata.org/entity/Q37687570

about

ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.Targeting the unfolded protein response in cancer.Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma.Imipridone family on successful TRAIL.ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways.Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.ICG-001 affects DRP1 activity and ER stress correlative with its anti-proliferative effect.A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.Role of Dopamine Receptors in the Anticancer Activity of ONC201.Targeting RAS - will GPR31 deliver us a new path forward?Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.Identification of more potent imipridones, a new class of anti-cancer agents.Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies.Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.The unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant colorectal cancer.Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor.Developing TRAIL/TRAIL death receptor-based cancer therapies.ONC201: a new treatment option being tested clinically for recurrent glioblastoma ONC201 demonstrates anti-tumorigenic and anti-metastatic activity in uterine serous carcinoma in vitro

P2860

Q38829723-0FC394FF-F25F-4EA4-ACFD-258249F49D74 Q39232751-AA03B04D-4CC1-4ACB-9DF4-FABDCD60CD40 Q41212464-16B8E658-91BC-484C-A5D2-3D729807C10F Q41566564-92BFF2EF-D255-48C7-BF33-DA57A94F07C8 Q41617112-4754C958-CF0D-477F-B45A-4DA2137429CB Q42365296-5FBFA9DD-DEF6-44E1-BBC3-231F2E56515A Q45559181-7F4324C9-981F-478D-AA64-5977388092FC Q47133947-FC9C5436-1790-42E4-8A9F-C469C8F0A857 Q47136169-6C0CFA49-05A2-44F7-8EB2-414917D2D002 Q47136932-6B603524-023F-46BF-860F-6889169CCE45 Q47325303-708AB5FE-5464-429E-8A19-F908D53FC751 Q48163220-E0352784-44B9-4A1F-B1B8-B40B5DBC5478 Q48177353-7F9C536B-155A-4ED2-B736-9487AB06AF72 Q48192170-E4A892D4-907F-4640-97E5-CA9E1F3115F8 Q50097295-B15BBFA9-1752-437F-B168-C71421832947 Q50204389-EF23F63A-7445-48C9-8D73-10BB6ADC8768 Q52658085-A49A51A6-621A-4CFB-A1BF-73A0B84A8E58 Q52684450-69FCF862-1E69-4A64-8297-9B8DEC87E9DA Q52720988-5DA557C3-DE82-437A-B584-928F118D5DD0 Q53701901-FC8DE809-5694-4734-AE67-6F72452867D0 Q55980927-07EB1292-954E-4FC7-9057-826A6F0A0056 Q57171344-B7A97915-9F21-4312-A492-1B1C8DB8C489

P2860

Discovery and clinical introduction of first-in-class imipridone ONC201.

http://www.wikidata.org/entity/Q37687570

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Discovery and clinical introduction of first-in-class imipridone ONC201.

@en

Discovery and clinical introduction of first-in-class imipridone ONC201.

@nl

type

label

Discovery and clinical introduction of first-in-class imipridone ONC201.

@en

Discovery and clinical introduction of first-in-class imipridone ONC201.

@nl

prefLabel

Discovery and clinical introduction of first-in-class imipridone ONC201.

@en

Discovery and clinical introduction of first-in-class imipridone ONC201.

@nl

P1433

Q37687570-85254790-4A69-4A99-BFFA-A57F29AA2FEB

P1476

Q37687570-8AE0C536-322E-4B3A-840B-60AB16789B3E

P2093

Q37687570-05E3F3B5-4C47-4235-999E-2B344C81CBE3

Q37687570-08534A55-D7E4-43C6-8F68-1F565299BEAC

Q37687570-0B9F48D0-0101-4595-A610-48EBF63D1894

Q37687570-27F066E4-8DD0-4037-97F4-53D013490EC7

Q37687570-3D78B4BE-D5D3-41BD-A4B1-2C2101E0B9EB

Q37687570-3EDC5824-D521-4532-9BA3-5999C52ECFC2

Q37687570-4059F3FA-DC95-408C-9E7C-297FD02923AD

Q37687570-4344B213-880E-4668-B228-FD4F2352E5B5

Q37687570-4846767E-237B-4583-A96B-A6ADDA7F630E

Q37687570-54E53254-6160-4B40-80DE-8DA6DD8A557D

P275

Q37687570-0C85AEF1-2BE5-4E3F-A9E9-AFADEF868552

P2860

Q37687570-09DC64AE-FDFA-4C03-9370-02313FC02E9C

Q37687570-0FD6CEED-7892-49FB-B605-145556C4823F

Q37687570-116D425E-16E8-4022-8BBF-EB0B3EA04FF6

Q37687570-148F8B09-BA81-48A9-96DF-7411C6B298D6

Q37687570-18E6F72C-1745-43EA-B538-DC6E66127780

Q37687570-1D205B3E-85AE-4277-BB66-AFBC0B21ECE8

Q37687570-2F21E1D1-28C6-42BC-910D-11120B275F35

Q37687570-33307535-1445-4CD4-A941-66F347609014

Q37687570-40096D80-B42F-4EA4-A11C-1CEDAC7B5DF0

Q37687570-4105890D-51F5-49AF-B7B2-A7A59193F6E0

P304

Q37687570-A44163B1-E166-4C8E-BB87-05E43F2554B8

P31

Q37687570-04BCFE47-4658-411B-96B0-EF3F9432D86A

Q37687570-D2B191D6-018D-49B2-A61E-56A3D861B319

P356

Q37687570-62E7F4B1-B316-4101-AFE4-3A76585C37EC

P407

Q37687570-721BA17F-61B2-47C0-A1A7-CB98CD5C96E5

P433

Q37687570-4144869F-86CF-4632-B4B6-23409713EA85

P478

Q37687570-93CEB2ED-A8CE-49F3-A38F-65B4E5D9A445

P50

Q37687570-0A760179-5E65-42E2-ABAA-CE63C24E6B7C

Q37687570-4BEC0DA2-507E-4136-A9AA-FD505540EBB8

Q37687570-9562E9A4-18AF-47BE-8953-E8099451C7E4

Q37687570-D49A44A3-10BF-47B9-BC29-61E872377249

Q37687570-F59F1502-2D25-4039-A570-9C3702AF976B

P5008

Q37687570-D2A175C6-8229-4EC0-80F7-EC6FC449E653

P577

Q37687570-268374F9-5D6A-406F-B6D5-35A2C4133074

Q37687570-33A165A8-DBEA-49FD-A1ED-ACE4E3449258

P698

Q37687570-42FCAB23-3F4A-4C95-9B6D-5A6B6893B015

P921

Q37687570-109FC867-DB49-49D2-A08B-42601C868521

P932

Q37687570-D74FCA27-E991-407D-AFC2-928B2D721EC4

P356

ONCOTARGET.11814

P1433

P1476

Discovery and clinical introduction of first-in-class imipridone ONC201.

@en

P2093

Amriti Lulla

http://www.w3.org/2001/XMLSchema#string

Avital Lev

http://www.w3.org/2001/XMLSchema#string

B Rao Nallaganchu

http://www.w3.org/2001/XMLSchema#string

Bora Lim

http://www.w3.org/2001/XMLSchema#string

C Leah B Kline

http://www.w3.org/2001/XMLSchema#string

Cyril Benes

http://www.w3.org/2001/XMLSchema#string

David T Dicker

http://www.w3.org/2001/XMLSchema#string

Gary L Olson

http://www.w3.org/2001/XMLSchema#string

Gen Sheng Wu

http://www.w3.org/2001/XMLSchema#string

Howard L Kaufman

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death

Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis

TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver

FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer

Role of endoplasmic reticulum stress in alpha-TEA mediated TRAIL/DR5 death receptor dependent apoptosis

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.

Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.

Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma

Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells.

P304

74380-74392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.11814

http://www.w3.org/2001/XMLSchema#string

P407

P433

45

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Olivier Elemento

Gautam Borthakur

Michael Andreeff

P5008

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2016-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27602582

http://www.w3.org/2001/XMLSchema#string

P921

P932

5342060

http://www.w3.org/2001/XMLSchema#string